Boston Ketamine Clinics: A Window Into Real-World Use

Boston Clinics Put Ketamine Therapy in the Spotlight

A May 2026 CBS News report profiled how health clinics across Boston are incorporating ketamine into mental health treatment — drawing on patient accounts, clinical perspectives, and a growing body of evidence supporting its use for conditions like treatment-resistant depression, anxiety, and PTSD. One patient's summary captures a sentiment that's increasingly common among those who've completed a ketamine series: "It's worth it."

The story reflects a broader shift underway in American psychiatry. Ketamine — once known primarily as an anesthetic or a substance of abuse — is being reframed in clinical settings as a rapid-acting intervention for patients who haven't responded adequately to conventional antidepressants. Boston, home to some of the country's leading academic medical centers, has become a microcosm of this national trend, with both hospital-affiliated programs and independent ketamine clinics now operating across the metro area. When a mainstream outlet like CBS News frames the question as "how are clinics using this" rather than "should they," it signals that the conversation has shifted from whether ketamine belongs in psychiatry to how it should be practiced.

What's Actually Happening in These Clinics

Most ketamine clinics in major cities like Boston offer one of two primary treatment formats: intravenous (IV) ketamine infusions administered at subanesthetic doses — typically 0.5 mg/kg over 40 minutes — or esketamine (Spravato), the FDA-approved intranasal formulation dosed at 56 mg or 84 mg under clinical supervision. Some practices also offer intramuscular (IM) ketamine, which sits between these two options in terms of bioavailability and duration of effect.

The standard induction protocol for IV ketamine involves six infusions over two to three weeks. The goal isn't sedation — it's a controlled, low-dose dissociative experience that triggers glutamate signaling and promotes neuroplasticity, particularly in the prefrontal circuits involved in mood regulation. Patients typically remain conscious but dissociated to varying degrees, and most report that the experience itself, while unusual, is manageable in a supervised clinical setting.

What the CBS News report highlights — and what the broader evidence base supports — is that this protocol often produces rapid symptom relief in people who have tried multiple antidepressants without meaningful benefit. Response rates in treatment-resistant depression studies typically fall in the 50–70% range for an initial series. Remission rates are lower, and durability remains the central clinical challenge. That last point deserves more attention than it usually gets in mainstream coverage.

The Durability Problem and What It Means for Maintenance

Patient testimonials like "it's worth it" are meaningful data points — but they need to be read carefully. For many people, the first series of infusions is genuinely transformative. The question that determines long-term value is more specific: how long does it last, and what does sustained treatment actually require?

The honest answer is that durability varies widely. Some patients maintain significant benefit for months after a single induction series, particularly when ketamine is combined with concurrent psychotherapy or an antidepressant medication that's been initiated or optimized alongside the infusions. Others find that effects begin to fade within weeks. Maintenance infusions — typically spaced monthly or bi-monthly after induction — are standard practice at most clinics, but protocols vary considerably because the evidence base for long-term maintenance scheduling is thinner than it is for the initial series.

This is a critical calibration point for anyone evaluating ketamine therapy. The treatment is not a one-time intervention for most people. It's better understood as an ongoing clinical relationship that requires periodic re-dosing — with the added complexity that each session carries some cognitive and cardiovascular load. Long-term use also raises questions about bladder health (ketamine cystopathy is a recognized risk at higher recreational doses, and while clinical doses are lower, the long-term picture for patients receiving years of maintenance treatment remains incompletely characterized) and the potential for psychological dependence. These questions haven't been resolved by the longitudinal data that currently exists.

Why Boston's Clinical Ecosystem Matters Beyond Boston

Boston isn't just another market for ketamine clinics. The city's concentration of academic medical centers — Massachusetts General Hospital, McLean Hospital, Brigham and Women's — means that some of the most carefully tracked observational data on real-world ketamine use is coming from this region. When Boston-area clinicians speak to national outlets like CBS News, they're typically drawing on larger patient cohorts and more rigorous outcome monitoring than smaller independent practices can provide. The optimism in the report likely reflects patients treated by experienced providers who have established screening criteria, dosing protocols, and safety infrastructure.

That context doesn't automatically translate to every ketamine clinic operating across the country, where standards remain variable in the absence of universal regulatory oversight. There's still no national credentialing body for ketamine providers, no standardized maintenance protocol, and no mandated long-term follow-up requirement. Individual clinic quality varies significantly.

For patients in or near Boston, the expanding clinical infrastructure is straightforwardly good news — more experienced providers, more institutional oversight, and the kind of competition that tends to improve care standards over time. For patients elsewhere, stories like this serve as a useful benchmark. Ask whether your clinic's approach resembles what's being practiced in well-resourced academic settings: thorough intake evaluation, conservative dosing adjustments, integration support, and monitoring that extends beyond the infusion chair. If those elements are present, the "it's worth it" outcome this CBS News patient described is a realistic target. If they're not, proceed with more caution.